A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/22990

Title:	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Authors:	Fuchs, C S Azevedo, S Okusaka, T Van Laethem, J-L Lipton, L R Riess, H Szczylik, C Moore, M J Peeters, M Bodoky, G Ikeda, M Melichar, B Nemecek, R Ohkawa, S Świeboda-Sadlej, A Tjulandin, S A Van Cutsem, E Loberg, R Haddad, V Gansert, J L Bach, B A Carrato, A View more
Keywords:	IGF-1 receptor biomarker ganitumab gemcitabine pancreatic cancer View more
Mesh:	Adenocarcinoma Administration, Intravenous Adult Aged Aged, 80 and over Antibodies, Monoclonal Antimetabolites, Antineoplastic Antineoplastic Combined Chemotherapy Protocols Biomarkers, Tumor Deoxycytidine Disease Progression Disease-Free Survival Double-Blind Method Drug Administration Schedule Female Humans Kaplan-Meier Estimate Male Middle Aged Pancreatic Neoplasms Proportional Hazards Models Time Factors Treatment Outcome View more
Issue Date:	May-2015
Citation:	Ann. Oncol..2015 May;(26)5:921-7
Abstract:	This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer.
PMID:	25609246
URI:	https://hdl.handle.net/20.500.12530/22990
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC4804122.pdf		186.01 kB	Adobe PDF	View/Open